Lurasidone for the treatment of depressive symptoms in schizophrenia: Analysis of 4 pooled, 6-week, placebo-controlled studies

CNS Spectrums

Volumn 20, Issue 2, 2015, Pages 140-147

  Nasrallah, Henry A ^a   Cucchiaro, Josephine B ^b   Mao, Yongcai ^b   Pikalov, Andrei A ^b   Loebel, Antony D ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Atypical antipsychotic; depression; depressive symptom; lurasidone; schizophrenia

Indexed keywords

BENZATROPINE; BIPERIDEN; DIPHENHYDRAMINE; LORAZEPAM; LURASIDONE; OLANZAPINE; PLACEBO; QUETIAPINE; TEMAZEPAM; TRIHEXYPHENIDYL; ZOLPIDEM; ISOINDOLE DERIVATIVE; NEUROLEPTIC AGENT; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY ASSESSMENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOM; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; DEPRESSIVE DISORDER; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOINDOLES; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; THIAZOLES; YOUNG ADULT;

EID: 84995356823     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852914000285     Document Type: Article

References (43)

1. th ed., text rev. Washington, DC: American Psychiatric Association; 2000.
2. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993; 50(2): 85-94.
3. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005; 2(5): e141.
4. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009; 35(2): 383-402.
5. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007; 90(1-3): 186-197.
6. Majadas S, Olivares J, Galan J, Diez T. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr Psychiatry. 2012; 53(2): 145-151.
7. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry. 2000; 157(9): 1379-1389.
8. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 1998; 55(3): 250-258.
9. Planansky K, Johnston R. Depressive syndrome in schizophrenia. Acta Psychiatr Scand. 1978; 57(3): 207-218.
10. Jin H, Zisook S, Palmer BW, Patterson TL, Heaton RK, Jeste DV. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. J Clin Psychiatry. 2001; 62(10): 797-803.
11. Reine G, Lançon C, Di Tucci S, Sapin C, Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand. 2003; 108(4): 297-303.
12. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999; 25(1): 157-171.
13. Birchwood M, Mason R, MacMillan F, Healy J. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med. 1993; 23(2): 387-395.
14. Oosthuizen P, Emsley R, Niehaus D, Koen L, Chiliza B. The relationships between depression and remission in first-episode psychosis. World Psychiatry. 2006; 5(3): 172-176.
15. 1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171-181.
16. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013; 225(3): 519-530.
17. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6): 829-836.
18. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013; 47(5): 670-677.
19. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011; 168 (9): 957-967.
20. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013; 145(1-3): 101-109.
21. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, doubleblind, active-controlled study. Int Clin Psychopharmacol. 2012; 27(3): 165-176.
22. Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013; 74(5): 507-515.
23. 7 receptor subtype. Neuropharmacology. 2013; 70: 211-217.
24. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014; 171(2): 160-168.
25. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014; 171(2): 169-177.
26. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134(4): 382-389.
27. Hawley CJ, Gale TM, Sivakumaran T. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002; 72(2): 177-184.
28. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008; 117(6): 412-419.
29. Latuda® (lurasidone hydrochloride) tablets, for oral use [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; 2013.
30. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol . 2010; 24(4 Suppl): 81-90.
31. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005; 62(3): 247-253.
32. Schwartz RC, Cohen BN. Psychosocial correlates of suicidal intent among patients with schizophrenia. Compr Psychiatry. 2001; 42(2): 118-123.
33. Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001; 15(2): 127-135.
34. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry. 2002; 63(6): 516-523.
35. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry. 1999; 156(4): 610-616.
36. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 1999; 45(4): 403-411.
37. Dollfus S, Olivier V, Chabot B, Deál C, Perrin E. Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res. 2005; 78(2-3): 157-159.
38. Kasper S. Treatment of depressive symptoms with quetiapine. Expert Rev Neurother. 2003; 3 (4): 417-423.
39. Myers JE, Thase ME. Risperidone: review of its therapeutic utility in depression. Psychopharmacol Bull. 2001; 35(4): 109-129.
40. Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003; 17(2): 210-215.
41. Zhao T, Park TW, Yang JC, et al. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial. Int Clin Psychopharmacol. 2012; 27(4): 184-190.
42. Baynes D, Mulholland C, Cooper SJ, et al. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res. 2000; 45(1-2): 47-56.
43. Zisook S, McAdams LA, Kuck J, et al. Depressive symptoms in schizophrenia. Am J Psychiatry. 1999; 156(11): 1736-1743.